EntreMed (ENMD) Initiates ENMD-2076 Phase 2
EntreMed, Inc. (Nasdaq: ENMD) announced the initiation of a single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stemline Therapeutics' (STML) SL-701 Receives FDA Orphan Designation as Glioma Treatment
- Lucas Energy, Inc. (LEI) Receives Notice of Default from Lender Louise H. Rogers
- Lucas Energy (LEI) Offers Financial Obligations And Operational Update
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!